CN109223712B - 氟比洛芬酯注射用乳剂及其制备方法 - Google Patents
氟比洛芬酯注射用乳剂及其制备方法 Download PDFInfo
- Publication number
- CN109223712B CN109223712B CN201811175197.7A CN201811175197A CN109223712B CN 109223712 B CN109223712 B CN 109223712B CN 201811175197 A CN201811175197 A CN 201811175197A CN 109223712 B CN109223712 B CN 109223712B
- Authority
- CN
- China
- Prior art keywords
- emulsion
- oil phase
- injection
- flurbiprofen axetil
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 128
- ALIVXCSEERJYHU-UHFFFAOYSA-N Flurbiprofen axetil Chemical compound FC1=CC(C(C)C(=O)OC(OC(C)=O)C)=CC=C1C1=CC=CC=C1 ALIVXCSEERJYHU-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 229950005941 flurbiprofen axetil Drugs 0.000 title claims abstract description 82
- 238000002347 injection Methods 0.000 title claims abstract description 67
- 239000007924 injection Substances 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 62
- 238000002156 mixing Methods 0.000 claims abstract description 58
- 238000010008 shearing Methods 0.000 claims abstract description 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 18
- 239000003381 stabilizer Substances 0.000 claims abstract description 16
- 239000008215 water for injection Substances 0.000 claims abstract description 15
- 230000003204 osmotic effect Effects 0.000 claims abstract description 13
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 239000003921 oil Substances 0.000 claims description 112
- 235000019198 oils Nutrition 0.000 claims description 112
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- 238000011049 filling Methods 0.000 claims description 18
- 239000011265 semifinished product Substances 0.000 claims description 16
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 239000003549 soybean oil Substances 0.000 claims description 12
- 235000012424 soybean oil Nutrition 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 238000007789 sealing Methods 0.000 claims description 11
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 9
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 claims description 9
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940083466 soybean lecithin Drugs 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 2
- 229960003511 macrogol Drugs 0.000 claims 1
- 229960004274 stearic acid Drugs 0.000 claims 1
- 235000013336 milk Nutrition 0.000 abstract description 39
- 239000008267 milk Substances 0.000 abstract description 39
- 210000004080 milk Anatomy 0.000 abstract description 39
- 239000003814 drug Substances 0.000 abstract description 31
- 239000002245 particle Substances 0.000 abstract description 23
- 238000005538 encapsulation Methods 0.000 abstract description 13
- 238000004945 emulsification Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 10
- 230000008685 targeting Effects 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 5
- 239000012071 phase Substances 0.000 description 92
- 230000000052 comparative effect Effects 0.000 description 29
- 229940079593 drug Drugs 0.000 description 23
- 238000007667 floating Methods 0.000 description 21
- 238000009826 distribution Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 14
- 210000003022 colostrum Anatomy 0.000 description 12
- 235000021277 colostrum Nutrition 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 238000004061 bleaching Methods 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 7
- 229960002390 flurbiprofen Drugs 0.000 description 7
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000032798 delamination Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- -1 aldehyde ketone Chemical class 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical class [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- MHZZQFJGUZUBCN-UHFFFAOYSA-N propan-2-ol;2,2,4-trimethylpentane Chemical compound CC(C)O.CC(C)CC(C)(C)C MHZZQFJGUZUBCN-UHFFFAOYSA-N 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Description
Ke | 20min | 30min | 40min | 60min | |
实施例1 | 0.27 | 无明显漂油 | 无明显漂油 | 无明显漂油 | 轻微漂油 |
实施例2 | 0.28 | 无明显漂油 | 无明显漂油 | 无明显漂油 | 轻微漂油 |
实施例3 | 0.37 | 无明显漂油 | 无明显漂油 | 无明显漂油 | 轻微漂油 |
实施例4 | 0.18 | 无明显漂油 | 无明显漂油 | 无明显漂油 | 轻微漂油 |
实施例5 | 0.15 | 无明显漂油 | 无明显漂油 | 无明显漂油 | 轻微漂油 |
对比例1 | 0.63 | 无明显漂油 | 轻微漂油 | 轻微分层 | 明显分层、破乳 |
对比例2 | 0.72 | 无明显漂油 | 轻微漂油 | 轻微分层 | 明显分层、破乳 |
对比例3 | 0.65 | 无明显漂油 | 轻微漂油 | 轻微分层 | 明显分层、破乳 |
Claims (7)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811175197.7A CN109223712B (zh) | 2018-10-10 | 2018-10-10 | 氟比洛芬酯注射用乳剂及其制备方法 |
PCT/CN2019/072562 WO2020073559A1 (zh) | 2018-10-10 | 2019-01-21 | 氟比洛芬酯注射用乳剂及其制备方法 |
US16/652,388 US11839590B2 (en) | 2018-10-10 | 2019-01-21 | Flurbiprofen axetil emulsion for injection and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811175197.7A CN109223712B (zh) | 2018-10-10 | 2018-10-10 | 氟比洛芬酯注射用乳剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109223712A CN109223712A (zh) | 2019-01-18 |
CN109223712B true CN109223712B (zh) | 2020-06-02 |
Family
ID=65055397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811175197.7A Active CN109223712B (zh) | 2018-10-10 | 2018-10-10 | 氟比洛芬酯注射用乳剂及其制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11839590B2 (zh) |
CN (1) | CN109223712B (zh) |
WO (1) | WO2020073559A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109223712B (zh) * | 2018-10-10 | 2020-06-02 | 武汉大安制药有限公司 | 氟比洛芬酯注射用乳剂及其制备方法 |
CN111296730A (zh) * | 2020-03-06 | 2020-06-19 | 广州市食品工业研究所有限公司 | 一种稳定性好的叶黄素纳米乳液及其制备方法 |
CN111671718B (zh) * | 2020-06-04 | 2022-04-26 | 山西普德药业有限公司 | 一种氟比洛芬酯注射液及其制备方法 |
CN112586742A (zh) * | 2020-12-15 | 2021-04-02 | 山东永春堂集团有限公司 | 一种元宝枫油乳剂的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1720031A (zh) * | 2002-12-06 | 2006-01-11 | 株式会社大塚制药工场 | 含丙泊酚的脂肪乳剂 |
CN102512367A (zh) * | 2011-12-26 | 2012-06-27 | 西安力邦制药有限公司 | 新型二十二碳六烯酸(dha)脂肪乳制剂配方和制备方法 |
CN102670502A (zh) * | 2012-05-17 | 2012-09-19 | 北京阜康仁生物制药科技有限公司 | S(+)-氟比洛芬酯注射乳剂 |
CN102988291A (zh) * | 2012-12-13 | 2013-03-27 | 哈药集团技术中心 | 一种氟比洛芬酯脂肪乳注射液组合物及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3722540A1 (de) * | 1987-07-08 | 1989-01-19 | Fresenius Ag | Fettemulsion, verfahren zu ihrer herstellung und ihre verwendung |
CN104188905B (zh) | 2014-08-28 | 2016-08-24 | 河北一品制药有限公司 | 一种稳定的氟比洛芬酯微纳米乳液及其制备方法 |
CN104434901B (zh) | 2014-11-12 | 2016-03-02 | 桂林澳林制药有限责任公司 | 一种氟比洛芬酯的药物组合物 |
CN104922065B (zh) | 2015-06-11 | 2018-01-02 | 北京蓝丹医药科技有限公司 | 一种稳定的氟比洛芬酯药物组合物 |
KR20190110563A (ko) * | 2017-02-07 | 2019-09-30 | 큐피가부시키가이샤 | 지방 유제, 및 그 제조 방법, 지방 유제의 안정성을 향상시키는 방법, 그리고 지방 유제의 안정성 향상제 |
CN109223712B (zh) * | 2018-10-10 | 2020-06-02 | 武汉大安制药有限公司 | 氟比洛芬酯注射用乳剂及其制备方法 |
-
2018
- 2018-10-10 CN CN201811175197.7A patent/CN109223712B/zh active Active
-
2019
- 2019-01-21 WO PCT/CN2019/072562 patent/WO2020073559A1/zh active Application Filing
- 2019-01-21 US US16/652,388 patent/US11839590B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1720031A (zh) * | 2002-12-06 | 2006-01-11 | 株式会社大塚制药工场 | 含丙泊酚的脂肪乳剂 |
CN102512367A (zh) * | 2011-12-26 | 2012-06-27 | 西安力邦制药有限公司 | 新型二十二碳六烯酸(dha)脂肪乳制剂配方和制备方法 |
CN102670502A (zh) * | 2012-05-17 | 2012-09-19 | 北京阜康仁生物制药科技有限公司 | S(+)-氟比洛芬酯注射乳剂 |
CN102988291A (zh) * | 2012-12-13 | 2013-03-27 | 哈药集团技术中心 | 一种氟比洛芬酯脂肪乳注射液组合物及其制备方法 |
Non-Patent Citations (3)
Title |
---|
10%静注脂肪乳的制备与性质考察;董广金;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20110515(第5期);E079-26 * |
分步乳化法在制备乳化石蜡中的应用;郭建彬,等;《科技风》;20150315(第5期);第124页 * |
氟比洛芬酯脂微球注射液的制备及质量研究;陆军,等;《天津药学》;20150628;第27卷(第3期);第18-21页 * |
Also Published As
Publication number | Publication date |
---|---|
US11839590B2 (en) | 2023-12-12 |
CN109223712A (zh) | 2019-01-18 |
US20210220303A1 (en) | 2021-07-22 |
WO2020073559A1 (zh) | 2020-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109223712B (zh) | 氟比洛芬酯注射用乳剂及其制备方法 | |
CN103110579B (zh) | 前列地尔注射剂 | |
CN101396346B (zh) | 紫杉醇脂质复合物 | |
WO2022160971A1 (zh) | 一种含有难溶性药物的浓缩液以及由其制备的乳剂 | |
CN105287406B (zh) | 一种丙泊酚脂质体冻干制剂及其制备方法 | |
Dhadde et al. | An overview on multiple emulsions | |
CN103816120B (zh) | 含有维生素k1的脂肪乳剂 | |
JP6907243B2 (ja) | 医薬目的のレスベラトロール可溶化製品 | |
CN104523591B (zh) | 无致敏性、无痛丙泊酚脂肪微乳冻干制剂配方和制备方法 | |
CN101810577A (zh) | 治疗肿瘤的棉酚静脉注射脂肪乳剂 | |
Xin et al. | Development of licorice flavonoids loaded microemulsion for transdermal delivery using CCD-optimal experimental approach: formulation development and characterization | |
CN109549924A (zh) | Sklb023混合胶束及其制备方法和用途 | |
CN101204373A (zh) | 紫杉醇脂质微球注射液及其制备方法 | |
CN109939071B (zh) | 一种红景天苷-维生素e双相前体脂质体的制备方法 | |
MX2012012855A (es) | Emulsion inyectable de un agente hipnotico sedante. | |
CN1965805A (zh) | 辅酶q10亚微乳注射液及制备方法 | |
CN109330994A (zh) | 一种榄香烯固体脂质纳米粒及其制备方法 | |
CN109806226A (zh) | 维生素k1脂肪乳注射液的用途 | |
CN109985004A (zh) | 氟比洛芬酯脂肪乳注射液、其制备方法及应用 | |
CN105476957B (zh) | 一种阿可拉定注射剂及其制备方法和用途 | |
CN105919974B (zh) | 鲑鱼降钙素磷脂复合物及其脂质纳米粒和制备方法 | |
KR100524700B1 (ko) | 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용약제 조성물 | |
CN113057940B (zh) | 1,8-桉叶油素乳剂及其制备方法 | |
CN114452258B (zh) | 利拉鲁肽脂质体制剂及其制备方法和应用 | |
CN104906050B (zh) | 一种莲心碱脂微球制剂及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 430000 Jinyin Lake Ecological Park, Dongxihu District, Wuhan City, Hubei Province Patentee after: Yuanda Life Science (Wuhan) Co.,Ltd. Address before: 430040 Jinyin Lake Ecological Park, Dongxihu District, Wuhan City, Hubei Province Patentee before: WUHAN DOCAN PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Emulsion for flurbiprofen axetil injection and its preparation method Effective date of registration: 20220224 Granted publication date: 20200602 Pledgee: Wuhan area branch of Hubei pilot free trade zone of Bank of China Ltd. Pledgor: Yuanda Life Science (Wuhan) Co.,Ltd. Registration number: Y2022420000043 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230403 Granted publication date: 20200602 Pledgee: Wuhan area branch of Hubei pilot free trade zone of Bank of China Ltd. Pledgor: Yuanda Life Science (Wuhan) Co.,Ltd. Registration number: Y2022420000043 |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 430000 No.1 Xiaoxiang West Road, Dongxihu District, Wuhan City, Hubei Province Patentee after: Yuanda Medical Nutrition Science (Wuhan) Co.,Ltd. Country or region after: China Address before: 430000 Jinyin Lake Ecological Park, Dongxihu District, Wuhan City, Hubei Province Patentee before: Yuanda Life Science (Wuhan) Co.,Ltd. Country or region before: China |